Latest news
Radioligand Therapy Is Building Its Evidence Base. Now Build the Infrastructure.
Phase III COMPETE data published in The Lancet show ¹⁷⁷Lu-edotreotide improved progression-free survival and response rate versus everolimus in advanced GEP-NETs. The policy question is no longer whether radioligand therapy is serious. It is whether systems are.
Bangladesh’s Dengue Alarm Is Already Ringing
Sleep is now cardiovascular prevention. Health systems still treat it like lifestyle advice
The GLP-1 boom still needs exercise policy
Europe Opens Another Lung Cancer Door to China-Origin Immunotherapy
In Australia, Cancer Medicine Delays Cost More Than Time
ADHD Does Not Stop Being ADHD When Anxiety Walks Into the Room
Wellness Powder Sent 32 People to Hospital
Fungal Disease Was Left Out of the AMR Fight
Pharmacists are becoming the front door for cardiometabolic care. Policy is still treating them like the back office
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.